Advanced Good Cell Culture Practice for Human Primary, Stem Cell-Derived and Organoid Models as well as Microphysiological Systems

Altex

Volumn 35, Issue 3, 2018, Pages 353-378

  Pamies, David ^a   Bal Price, Anna ^b   Chesné, Christophe ^c   Coecke, Sandra ^b   Dinnyes, Andras ^d,e   Eskes, Chantra ^f   Grillari, Regina ^g,h   Gstraunthaler, Gerhard ⁱ   Hartung, Thomas ^a,j   Jennings, Paul ^k   Leist, Marcel ^j   Martin, Ulrich ^l   Passier, Robert ^m,n   Schwamborn, Jens C ^o   Stacey, Glyn N ^p   Ellinger Ziegelbauer, Heidrun ^q   Daneshian, Mardas ^j  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOINT RESEARCH CENTRE   (Italy)

^c Biopredic sarl   (France)

^d BIOTALENTUM LTD   (Hungary)

^e SZENT ISTVÁN UNIVERSITY   (Hungary)

^f SeCAM Services and Consultation on Alternative Methods   (Switzerland)

^g UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^h Evercyte GmbH   (Austria)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j UNIVERSITY OF KONSTANZ   (Germany)

^k AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m UNIVERSITY OF TWENTE   (Netherlands)

ⁿ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^p NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^q BAYER AG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANIMAL TESTING ALTERNATIVE; CELL CULTURE TECHNIQUE; EDUCATION; GERMANY; HUMAN; IN VITRO STUDY; ORGANOID; PHYSIOLOGY; PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; PROCEDURES; QUALITY CONTROL; STANDARDS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; CELL CULTURE TECHNIQUES; EDUCATION; GERMANY; GUIDELINES AS TOPIC; HUMANS; IN VITRO TECHNIQUES; ORGANOIDS; PLURIPOTENT STEM CELLS; QUALITY CONTROL;

EID: 85055522034     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.1710081     Document Type: Article

References (150)

1. Achilli, T. M., Meyer, J. and Morgan, J. R. (2012). Advances in the formation, use and understanding of multi-cellular spheroids. Expert Opin Biol Ther 12, 1347-1360. doi:10.1517/147 12598.2012.707181
2. Ackermann, M., Lachmann, N., Hartung, S. et al. (2014). Promoter and lineage independent anti-silencing activity of the A2 ubiquitous chromatin opening element for optimized human pluripotent stem cell-based gene therapy. Biomaterials 35, 1531-1542. doi:10.1016/j.biomaterials.2013.11.024
3. Alépée, N., Bahinski, T., Daneshian, M. et al. (2014). State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX 31, 441-477. doi:10.14573/ altex1406111
4. Andrews, P. W., Baker, D., Benvinisty, N. et al. (2015). Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications. Regen Med 10, 2 Suppl, 1-44. doi:10.2217/rme.14.93
5. Anonymous (2015). Do we need an ethics of self-organizing tissue? Nat Methods 12, 895. doi:10.1038/nmeth.3618
6. Avior, Y., Sagi, I. and Benvenisty, N. (2016). Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol 17, 170-182. doi:10.1038/nrm.2015.27
7. Balijepalli, A. and Sivaramakrishan, V. (2017). Organs-on-chips: Research and commercial perspectives. Drug Discov Today 22, 397-403. doi:10.1016/j.drudis.2016.11.009
8. Balls, M. (2012). Ethical issues in the production of human cell lines and stem cell lines. Altern Lab Anim 40, 59-61.
9. Begley, C. G. and Ellis, L. M. (2012). Drug development: Raise standards for preclinical cancer research. Nature 483, 531-533. doi:10.1038/483531a
10. Bellin, M., Marchetto, M. C., Gage, F. H. and Mummery, C. L. (2012). Induced pluripotent stem cells: The new patient? Nat Rev Mol Cell Biol 13, 713-726. doi:10.1038/nrm3448
11. Benabdellah, K., Cobo, M., Munoz, P. et al. (2011). Development of an all-in-one lentiviral vector system based on the original TetR for the easy generation of Tet-ON cell lines. PLoS One 6, e23734. doi:10.1371/journal.pone.0023734
12. Bhushan, A., Senutovitch, N., Bale, S. S. et al. (2013). Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Res Ther 4, Suppl 1, S16. doi:10.1186/scrt377
13. Borstlap, J., Stacey, G., Kurtz, A. et al. (2008). First evaluation of the European hESCreg. Nat Biotechnol 26, 859-860. doi:10.1038/nbt0808-859
14. Brazma, A. (2009). Minimum information about a microarray experiment (MIAME) – Successes, failures, challenges. Sci-entificWorldJournal 9, 420-423. doi:10.1100/tsw.2009.57
15. Burrows, C. K., Banovich, N. E., Pavlovic, B. J. et al. (2016). Genetic variation, not cell type of origin, underlies the majority of identifiable regulatory differences in iPSCs. PLoS Genet 12, e1005793. doi:10.1371/journal.pgen.1005793
16. Buta, C., David, R., Dressel, R. et al. (2013). Reconsidering pluripotency tests: Do we still need teratoma assays? Stem Cell Res 11, 552-562. doi:10.1016/j.scr.2013.03.001
17. Chang, C. W., Lai, Y. S., Pawlik, K. M. et al. (2009). Polycistronic lentiviral vector for “hit and run” reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27, 1042-1049. doi:10.1002/stem.39
18. Chapman, J. R., Taylor, M. R. and Boulton, S. J. (2012). Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 47, 497-510. doi:10.1016/j.molcel.2012.07.029
19. Cho, S. W., Kim, S., Kim, J. M. and Kim, J. S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230-232. doi:10.1038/nbt.2507
20. Choulika, A., Perrin, A., Dujon, B. and Nicolas, J. F. (1995). Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol Cell Biol 15, 1968-1973. doi:10.1128/ MCB.15.4.1968
21. Coecke, S., Balls, M., Bowe, G. et al. (2005). Guidance on good cell culture practice – A report of the second ECVAM task force on good cell culture practice. Altern Lab Anim 33, 261-287.
22. Cooper-Hannan, R., Harbell, J. W., Coecke, S. et al. (1999). The principles of good laboratory practice: Application to in vitro toxicology studies – The report and recommendations of ECVAM Workshop 37. Altern Lab Anim 27, 539-577.
23. Cox, D. B., Platt, R. J. and Zhang, F. (2015). Therapeutic genome editing: Prospects and challenges. Nat Med 21, 121-131. doi:10.1038/nm.3793
24. De Clercq, E., Kaye, J., Wolf, S. M. et al. (2017). Returning results in biobank research: Global trends and solutions. Genet Test Mol Biomarkers 21, 128-131. doi:10.1089/gtmb.2016.0394
25. Dhar, D. and Hsi-En Ho, J. (2009). Stem cell research policies around the world. Yale J Biol Med 82, 113-115.
26. Ding, Q., Lee, Y. K., Schaefer, E. A. et al. (2013a). A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12, 238-251. doi:10.1016/j. stem.2012.11.011
27. Ding, Q., Regan, S. N., Xia, Y. et al. (2013b). Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393-394. doi:10.1016/j.stem.2013.03.006
28. Drexler, H. G. and Uphoff, C. C. (2002). Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 39, 75-90. doi:10.1023/A:1022913015916
29. Drexler, H. G., Uphoff, C. C., Dirks, W. G. and Macleod, R. A. F. (2002). Mix-ups and mycoplasma: The enemies within. Leuk Res 26, 329-333. doi:10.1016/S0145-2126(01)00136-9
30. Duval, K., Grover, H., Han, L. H. et al. (2017). Modeling physiological events in 2D vs. 3D cell culture. Physiology 32, 266-277. doi:10.1152/physiol.00036.2016
31. EMA (2011). European Medicines Agency “Reflection paper on stem cell-based medicinal products”. EMA/CAT/571134/2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500101692.pdf
32. EMA (2014). European Medicines Agency “Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission”. EMA/CHMP/BWP/187338/2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2016/04/WC500205447.pdf
33. Eskes, C., Boström, A.-C., Bowe, G. et al. (2017). Good cell culture practices & in vitro toxicology. Toxicol In Vitro 45, 272-277. doi:10.1016/j.tiv.2017.04.022
34. Fatehullah, A., Tan, S. H. and Barker, N. (2016). Organoids as an in vitro model of human development and disease. Nat Cell Biol 18, 246-254. doi:10.1038/ncb3312
35. Fatica, A. and Bozzoni, I. (2014). Long non-coding RNAs: New players in cell differentiation and development. Nat Rev Genet 15, 7-21. doi:10.1038/nrg3606
36. Ferrario, D., Brustio, R. and Hartung, T. (2014). Glossary of reference terms for alternative test methods and their validation. ALTEX 31, 319-335. doi:10.14573/altex.140331
37. Frankart, A., Malaisse, J., De Vuyst, E. et al. (2012). Epidermal morphogenesis during progressive in vitro 3D reconstruction at the air-liquid interface. Exp Dermatol 21, 871-875. doi:10.1111/exd.12020
38. Fricain, J. C., De Olivera, H., Devillard, R. et al. (2017). (3D bioprinting in regenerative medicine and tissue engineering). Med Sci (Paris) 33, 52-59. doi:10.1051/medsci/20173301009
39. Fu, Y., Foden, J. A., Khayter, C. et al. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31, 822-826. doi:10.1038/nbt.2623
40. Fu, Y., Sander, J. D., Reyon, D. et al. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32, 279-284. doi:10.1038/nbt.2808
41. Galietta, L. J., Haggie, P. M. and Verkman, A. S. (2001). Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 499, 220-224. doi:10.1016/S0014-5793(01)02561-3
42. Ghaemmaghami, A. M., Hancock, M. J., Harrington, H. et al. (2012). Biomimetic tissues on a chip for drug discovery. Drug Discov Today 17, 173-181. doi:10.1016/j.drudis.2011.10.029
43. Goldberg, I. G., Allan, C., Burel, J. M. et al. (2005). The open microscopy environment (OME) data model and XML file: Open tools for informatics and quantitative analysis in biological imaging. Genome Biol 6, R47. doi:10.1186/gb-2005-6-5-r47
44. Gonzales, F., Boué, S. and Izpisúa Belmonte, J. C. (2011). Methods for making induced pluripotent stem cells:reprogramming à la carte. Nat Rev Genet 12, 231-242. doi:10.1038/nrg2937
45. Gonzalez, F., Zhu, Z., Shi, Z. D. et al. (2014). An iCRISPR Platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15, 215-226. doi:10.1016/j.stem.2014.05.018
46. Gropp, M., Itsykson, P., Singer, O. et al. (2003). Stable genetic modification of human embryonic stem cells by lentiviral vectors. Mol Ther 7, 281-287. doi:10.1016/S1525-0016(02)00047-3
47. Gruh, I., Wunderlich, S., Winkler, M. et al. (2008). Human CMV immediate-early enhancer: A useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene Med 10, 21-32. doi:10.1002/jgm.1122
48. Gstraunthaler, G. and Hartung, T. (1999). Bologna declaration toward good cell culture practice. Altern Lab Anim 27, 206.
49. Hartung, T., Balls, M., Bardouille, C. et al. (2002). Good cell culture practice. ECVAM good cell culture practice task force report 1. Altern Lab Anim 30, 407-414.
50. Hartung, T. (2007). Food for thought ... on cell culture. ALTEX 24, 143-152. doi:10.14573/altex.2007.3.143
51. Hartung, T. (2014). 3D – A new dimension of in vitro research. Adv Drug Deliv Rev 69-70, vi. doi:10.1016/j.addr.2014.04.003
52. Hartung, T. (2017). Perspectives on in vitro to in vivo extrapolations. J Appl In Vitro Toxicol, in press. doi:10.1089/ aivt.2016.0026
53. Haycock, J. W. (2011). 3D cell culture: A review of current approaches and techniques. Methods Mol Biol 695, 1-15. doi:10.1007/978-1-60761-984-0_1
54. Hogberg, H. T., Bressler, J., Christian, K. M. et al. (2013). Toward a 3D model of human brain development for studying gene/environment interactions. Stem Cell Res Ther 4, Suppl 1, S4. doi:10.1186/scrt365
55. Hong, N., Yang, G. H., Lee, J. and Kim, G. (2017). 3D bioprinting and its in vivo applications. J Biomed Mater Res B Appl Biomater 106, 444-459. doi:10.1002/jbm.b.33826
56. Hou, P., Li, Y., Zhang, X. et al. (2013). Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341, 651-654. doi:10.1126/science.1239278
57. Howden, S. E., Maufort, J. P., Duffin, B. M. et al. (2015). Simultaneous reprogramming and gene correction of patient fibroblasts. Stem Cell Reports 5, 1109-1118. doi:10.1016/j. stemcr.2015.10.009
58. Hsu, P. D., Scott, D. A., Weinstein, J. A. et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31, 827-832. doi:10.1038/nbt.2647
59. Huh, D., Hamilton, G. A. and Ingber, D. E. (2011). From 3D cell culture to organs-on-chips. Trends Cell Biol 21, 745-754. doi:10.1016/j.tcb.2011.09.005
60. Jennings, P., Aschauer, L., Wilmes, A. and Gstraunthaler, G. (2014). Renal cell culture. In A. Bal-Price and P. Jennings (eds.), In Vitro Toxicology Systems, Methods in Pharmacology and Toxicology (79-101). New York: Springer. doi:10.1007/978-1-4939-0521-8_4
61. Jennings, P. (2015). The future of in vitro toxicology. Toxicol In Vitro 29, 1217-1221. doi:10.1016/j.tiv.2014.08.011
62. Kameoka, S., Babiarz, J., Kolaja, K. and Chiao, E. (2014). A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci 137, 76-90. doi:10.1093/toxsci/ kft239
63. Kilic, O., Pamies, D., Lavell, E. et al. (2016). Brain-on-a-chip model enables analysis of human neuronal differentiation and chemotaxis. Lab Chip 16, 4152-4162. doi:10.1039/ C6LC00946H
64. Kim, J. H., Kurtz, A., Yuan, B. Z. et al. (2017). Report of the international stem cell banking initiative workshop activity: Current hurdles and progress in seed-stock banking of human pluripotent stem cells. Stem Cells Transl Med 6, 1956-1962. doi:10.1002/sctm.17-0144
65. Kim, K., Doi, A., Wen, B. et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-290. doi:10.1038/nature09342
66. Kimbrel, E. A. and Lanza, R. (2015). Current status of pluripotent stem cells: Moving the first therapies to the clinic. Nat Rev Drug Discov 14, 681-692. doi:10.1038/nrd4738
67. King, N. M. and Perrin, J. (2014). Ethical issues in stem cell research and therapy. Stem Cell Res Ther 5, 85. doi:10.1186/ scrt474
68. Kleensang, A,. Vantangoli, M., Odwin-DaCosta, S. et al. (2016). Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Sci Rep 6, 28994-28994. doi:10.1038/srep28994
69. Knight, E. and Przyborski, S. (2015). Advances in 3D cell culture technologies enabling tissue-like structures to be created in vitro. J Anat 227, 746-756. doi:10.1111/joa.12257
70. Kolaja, K. (2014). Stem cells and stem cell-derived tissues and their use in safety assessment. J Biol Chem 289, 4555-4561. doi:10.1074/jbc.R113.481028
71. Kyttälä, A., Moraghebi, R., Valensisi, C. et al. (2016). Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential. Stem Cell Reports 6, 200-212. doi:10.1016/j.stemcr.2015.12.009
72. Lancaster, M. A., Renner, M., Martin, C. A. et al. (2013). Cerebral organoids model human brain development and microcephaly. Nature 501, 373-379. doi:10.1038/nature12517
73. Li, X. J., Valadez, A. V., Zuo, P. and Nie, Z. (2012). Microfluidic 3D cell culture: Potential application for tissue-based bioassays. Bioanalysis 4, 1509-1525. doi:10.4155/bio.12.133
74. Li, Z. and Cui, Z. (2014). Three-dimensional perfused cell culture. Biotechnol Adv 32, 243-254. doi:10.1016/j.biotechadv. 2013.10.006
75. Liang, G. and Zhang, Y. (2013a). Embryonic stem cell and induced pluripotent stem cell: An epigenetic perspective. Cell Res 23, 49-69. doi:10.1038/cr.2012.175
76. Liang, G. and Zhang, Y. (2013b). Genetic and epigenetic variations in iPSCs: Potential causes and implications for application. Stem Cell 13, 149-159. doi:10.1016/j. stem.2013.07.001
77. Liu, J., Jones, K. L., Sumer, H. and Verma, P. J. (2009). Stable transgene expression in human embryonic stem cells after simple chemical transfection. Mol Reprod Dev 76, 580-586. doi:10.1002/mrd.20983
78. Mali, P., Aach, J., Stranges, P. B. et al. (2013). CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31, 833-838. doi:10.1038/nbt.2675
79. Malik, N. and Rao, M. S. (2013). A review of the methods for human iPSC derivation. Methods Mol Biol 997, 23-33. doi:10.1007/978-1-62703-348-0_3
80. Marx, U. (2012). Trends in cell culture technology. Adv Exp Med Biol 745, 26-46. doi:10.1007/978-1-4614-3055-1_3
81. Marx, U., Walles, H., Hoffmann, S. et al. (2012). “Human-on-a-chip” developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40, 235-257.
82. Marx, U., Andersson, T. B., Bahinski, A. et al. (2016). Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing using animals. ALTEX 33, 272-321. doi:10.14573/altex.1603161
83. Maschmeyer, I., Hasenberg, T., Jaenicke, A. et al. (2015). Chip-based human liver-intestine and liver-skin co-cultures – A first step toward systemic repeated dose substance testing in vitro. Eur J Pharm Biopharm 95, 77-87. doi:10.1016/j. ejpb.2015.03.002
84. Merkert, S., Wunderlich, S., Bednarski, C. et al. (2014). Efficient designer nuclease-based homologous recombination enables direct PCR screening for footprintless targeted human pluripotent stem cells. Stem Cell Reports 2, 107-118. doi:10.1016/j. stemcr.2013.12.003
85. Merkert, S. and Martin, U. (2016). Targeted genome engineering using designer nucleases: State of the art and practical guidance for application in human pluripotent stem cells. Stem Cell Res 16, 377-386. doi:10.1016/j.scr.2016.02.027
86. Miller, J. C., Tan, S., Qiao, G. et al. (2011). A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29, 143-148. doi:10.1038/nbt.1755
87. Monzel, A. S., Smits, L. M., Hemmer, K. et al. (2017). Derivation of human midbrain-specific organoids from neuroepithelial stem cells. Stem Cell Reports 8, 1144-1154. doi:10.1016/j. stemcr.2017.03.010
88. Moreno, E. L., Hachi, S., Hemmer, K. et al. (2015). Differentiation of neuroepithelial stem cells into functional dopaminergic neurons in 3D microfluidic cell culture. Lab Chip 15, 2419-2428. doi:10.1039/C5LC00180C
89. Müller, F. J., Schuldt, B. M., Williams, R. et al. (2011). A bioinformatic assay for pluripotency in human cells. Nat Methods 8, 315-317. doi:10.1038/nmeth.1580
90. Nielen, M. G., de Vries, S. A. and Geijsen, N. (2013). European stem cell research in legal shackles. EMBO J 32, 3107-3111. doi:10.1038/emboj.2013.249
91. Page, H., Flood, P. and Reynaud, E. G. (2013). Three-dimensional tissue cultures: Current trends and beyond. Cell Tissue Res 352, 123-131. doi:10.1007/s00441-012-1441-5
92. st century toxicology. Chem Res Toxicol 30, 43-52. doi:10.1021/acs.chemrestox.6b00269
93. Pamies, D., Bal-Price, A., Simeonov, A. et al. (2017a). Good cell culture practice for stem cells and stem-cell-derived models. ALTEX 34, 95-132. doi:10.14573/altex.1607121
94. Pamies, D., Barreras, P., Block, K. et al. (2017b). A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity. ALTEX 34, 362-376. doi:10.14573/altex.1609122
95. Passier, R., Orlova, V. and Mummery, C. (2016). Complex tissue and disease modeling using hiPSCs. Cell Stem Cell 18, 309-321. doi:10.1016/j.stem.2016.02.011
96. Pattanayak, V., Lin, S., Guilinger, J. P. et al. (2013). High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31, 839-843. doi:10.1038/nbt.2673
97. Pera, M. F., de Wert, G., Dondorp, W. et al. (2015). What if stem cells turn into embryos in a dish? Nat Methods 12, 917-919. doi:10.1038/nmeth.3586
98. Perestrelo, A. R., Aguas, A. C., Rainer, A. and Forte, G. (2015). Microfluidic organ/body-on-a-chip devices at the convergence of biology and microengineering. Sensors 15, 31142-31170. doi:10.3390/s151229848
99. Pettersen, E. O., Larsen, L. H., Ramsing, N. B. and Ebbesen, P. (2005). Pericellular oxygen depletion during ordinary tissue culturing, measured with oxygen microsensors. Cell Prolif 38, 257-267. doi:10.1111/j.1365-2184.2005.00345.x
100. Pinheiro de Oliveira, T. F., Fonseca, A. A., Camargos, M. F. et al. (2013). Detection of contaminants in cell cultures, sera and trypsin. Biologicals 41, 407-414. doi:10.1016/j.biologicals. 2013.08.005
101. Plath, K. and Lowry, W. E. (2011). Progress in understanding reprogramming to the induced pluripotent state. Nat Rev Genet 12, 253-265. doi:10.1038/nrg2955
102. Porteus, M. H. and Carroll, D. (2005). Gene targeting using zinc finger nucleases. Nat Biotechnol 23, 967-973. doi:10.1038/ nbt1125
103. Prinz, F., Schlange, T. and Asadullah, K. (2011). Believe it or not: How much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10, 712. doi:10.1038/nrd3439-c1
104. Ravi, M., Paramesh, V., Kaviya, S. R. et al. (2015). 3D cell culture systems: Advantages and applications. J Cell Physiol 230, 16-26. doi:10.1002/jcp.24683
105. Rebelo, S. P., Dehne, E. M., Brito, C. et al. (2016). Validation of bioreactor and human-on-a-chip devices for chemical safety assessment. Adv Exp Med Biol 856, 299-316. doi:10.1007/978-3-319-33826-2_12
106. Rempel, E., Hoelting, L., Waldmann, T. et al. (2015). A transcriptome-based classifier to identify developmental toxicants by stem cell testing: Design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol 89, 1599-1618. doi:10.1007/s00204-015-1573-y
107. Reubinoff, B. E., Pera, M. F., Fong, C. Y. et al. (2000). Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat Biotechnol 18, 399-404. doi:10.1038/74447
108. Roth, A. and Singer, T. (2014). The application of 3D cell models to support drug safety assessment: Opportunities & challenges. Adv Drug Deliv Rev 69-70, 179-189. doi:10.1016/j. addr.2013.12.005
109. Rouet, P., Smih, F. and Jasin, M. (1994). Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci U S A 91, 6064-6068. doi:10.1073/pnas.91.13.6064
110. Sakurai, K., Kurtz, A., Stacey, G. et al. (2016). First proposal of minimum information about a cellular assay for regenerative medicine (MIACARM). Stem Cells Transl Med 5, 1345-1361. doi:10.5966/sctm.2015-0393
111. Sato, T., Vries, R. G., Snippert, H. J. et al. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262-265. doi:10.1038/ nature07935
112. Schlaeger, T. M., Daheron, L., Brickler, T. R. et al. (2015). A comparison of non-integrating reprogramming methods. Nat Biotechnol 33, 58-63. doi:10.1038/nbt.3070
113. Schwanke, K., Merkert, S., Kempf, H. et al. (2014). Fast and efficient multitransgenic modification of human pluripotent stem cells. Hum Gene Ther Methods 25, 136-153. doi:10.1089/ hgtb.2012.248
114. Scott, C. W., Peters, M. F. and Dragan, Y. P. (2013). Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol Lett 219, 49-58. doi:10.1016/j. toxlet.2013.02.020
115. Seltmann, S., Lekschas, F., Muller, R. et al. (2016). hPSCreg – The human pluripotent stem cell registry. Nucleic Acids Res 44, D757-763. doi:10.1093/nar/gkv963
116. Siemen, H., Nix, M., Endl, E. et al. (2005). Nucleofection of human embryonic stem cells. Stem Cells Dev 14, 378-383. doi:10.1089/scd.2005.14.378
117. Slaymaker, I. M., Gao, L., Zetsche, B. et al. (2016). Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84-88. doi:10.1126/science.aad5227
118. Soares, F. A., Sheldon, M., Rao, M. et al. (2014). International coordination of large-scale human induced pluripotent stem cell initiatives: Wellcome Trust and ISSCR workshops white paper. Stem Cell Reports 3, 931-939. doi:10.1016/j.stemcr.2014.11.006 Sommer, C. A., Stadtfeld, M., Murphy, G. J. et al. (2009). Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27, 543-549. doi:10.1634/stemcells.2008-1075
119. Stacey, G., Doyle, A. and Hambleton, P. (eds.) (1998). Safety in Cell and Tissue Culture. Springer. doi:10.1007/978-94-011-4916-7
120. Stacey, G. (2012). Current developments in cell culture technology. Adv Exp Med Biol 745, 1-13. doi:10.1007/978-1-4614-3055-1_1
121. Stacey, G. N., Coecke, S., Price, A. et al. (2016). Ensuring the quality of stem cell derived models for toxicity testing. Adv Exp Med Biol 856, 259-297. doi:10.1007/978-3-319-33826-2_11
122. Subramanyam, D., Lamouille, S., Judson, R. L. et al. (2011). Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 29, 443-448. doi:10.1038/nbt.1862
123. Takahashi, K. and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. doi:10.1016/j. cell.2006.07.024
124. Takahashi, K., Tanabe, K., Ohnuki, M. et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872. doi:10.1016/j.cell.2007.11.019
125. Takebe, T., Zhang, R. R., Koike, H. et al. (2014). Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat Protoc 9, 396-409. doi:10.1038/ nprot.2014.020
126. 2+ indicator GCaMP2. Proc Natl Acad Sci U S A 103, 4753-4758. doi:10.1073/pnas.0509378103
127. Templin, C., Zweigerdt, R., Schwanke, K. et al. (2012). Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: Assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iodide symporter transgene expression. Circulation 126, 430-439. doi:10.1161/CIRCULATIONAHA. 111.087684
128. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S. et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147. doi:10.1126/science.282.5391.1145
129. Tsaioun, K., Blaauboer, B. J. and Hartung, T. (2016). Evidence-based absorption, distribution, metabolism, excretion and toxicity (ADMET) and the role of alternative methods. ALTEX 33, 343-358. doi:10.14573/altex.1610101
130. van der Valk, J., Bieback, K., Buta, C. et al. (2018). Fetal bovine serum (FBS): Past – present – future. ALTEX 35, 99-118. doi:10.14573/altex.1705101
131. van Duinen, V., Trietsch, S. J., Joore, J. et al. (2015). Microfluidic 3D cell culture: From tools to tissue models. Curr Opin Biotechnol 35, 118-126. doi:10.1016/j.copbio.2015.05.002
132. st century. ALTEX 28, 17-44. doi:10.14573/altex.2011.1.017
133. van Vliet, E., Daneshian, M., Beilmann, M. et al. (2014). Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 31, 479-493. doi:10.14573/altex.1405271
134. Vasquez, K. M., Marburger, K., Intody, Z. and Wilson, J. H. (2001). Manipulating the mammalian genome by homologous recombination. Proc Natl Acad Sci U S A 98, 8403-8410. doi:10.1073/pnas.111009698
135. Veres, A., Gosis, B. S., Ding, Q. et al. (2014). Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15, 27-30. doi:10.1016/j. stem.2014.04.020
136. Verkman, A. S., Lukacs, G. L. and Galietta, L. J. (2006). CFTR chloride channel drug discovery – Inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des 12, 2235-2247. doi:10.2174/138161206777585148
137. Waldman, A. S. (1992). Targeted homologous recombination in mammalian cells. Crit Rev Oncol Hematol 12, 49-64. doi:10.1016/1040-8428(92)90064-W
138. Wang, G., McCain, M. L., Yang, L. et al. (2014). Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 20, 616-623. doi:10.1038/nm.3545
139. Ware, B. R. and Khetani, S. R. (2017). Engineered liver platforms for different phases of drug development. Trends Biotechnol 35, 172-183. doi:10.1016/j.tibtech.2016.08.001
140. Welsh, M. J. and Smith, A. E. (1993). Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73, 1251-1254. doi:10.1016/0092-8674(93)90353-R
141. West, P. R., Weir, A. M., Smith, A. M. et al. (2010). Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol 247, 18-27. doi:10.1016/j.taap.2010.05.007
142. st meeting of the WHO Expert Committee on Biological Standardization, 18 to 22 October 2010, WHO, Geneva. http://www.who.int/biologicals/Cell_Substrates_clean_version_18_April.pdf (accessed 08.10.2017).
143. Wieser, M., Francisci, T., Lackner, D. et al. (submitted). CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells.
144. Wilmer, M. J., Ng, C. P., Lanz, H. L. et al. (2016). Kidney-on-a-chip technology for drug-induced nephrotoxicity screening. Trends Biotechnol 34, 156-170. doi:10.1016/j. tibtech.2015.11.001
145. Yoon, N. D., Lee, K. H., Lee, J. and Lee, S. H. (2015). 3D liver models on a microplatform: Well-defined culture, engineering of liver tissue and liver-on-a-chip. Lab Chip 15, 3822-3837. doi:10.1039/C5LC00611B
146. Ye, F., Chen, C., Qin, J. et al. (2015). Genetic profiling reveals an alarming rate of cross-contamination among human cell lines used in China. FASEB J 29, 4268-4272. doi:10.1096/ fj.14-266718
147. Yu, C., Liu, Y., Ma, T. et al. (2015). Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16, 142-147. doi:10.1016/j.stem.2015.01.003
148. Yu, J., Vodyanik, M. A., Smuga-Otto, K. et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920. doi:10.1126/science.1151526
149. Zhang, C. and van Noort, D. (2011). Cells in microfluidics. Top Curr Chem 304, 295-321. doi:10.1007/128_2011_147
150. Zhang, J., Wei, X., Zeng, R. et al. (2017). Stem cell culture and differentiation in microfluidic devices toward organ-on-a-chip. Future Sci OA 3, FSO187. doi:10.4155/fsoa-2016-0091